On April 28, 2020 Cellesce’s Board of Directors reported the appointment of Paul Jenkins as Interim CEO as from 28th April, 2020 (Press release, Cellesce, APR 28, 2020, View Source [SID1234556681]). Paul takes over as CEO from Mark Treherne, who has been CEO since May 2018, and will now focus on his other existing directorships.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

John Allbrook (Non-Executive Chairman of Cellesce) said, "On behalf of the Board I would like to thank Mark for his all his effort and accomplishments over the last 2 years, which have seen the Company make good progress. Under Mark’s stewardship the Company has taken significant steps forward in the development and deployment of its core Organoid Bioprocessing technology, partially funded by a series of successful grant applications. At the same time, the Company has started to gain commercial traction and realised strong revenue growth. I am delighted to welcome Paul Jenkins to Cellesce. These are extraordinary times and the Covid-19 pandemic is presenting all businesses with a unique set of challenges. I am confident with Paul at the helm that Cellesce will rise to these challenges and continue to build on the excellent foundations already in-place."

"Paul is a seasoned business development and senior management executive in Life Sciences. He has amassed a wealth of deal-making and investment experience across a variety of therapeutic areas. Paul’s previous roles include VP Business Development at Catalent, CEO at Adjuvantix, and VP Business Development at West Pharmaceutical Services. Paul is also a strategic advisor to Yorkshire Cancer Research."

Cellesce has developed a new patented bioprocessing technology for the growth and expansion of Patient-Derived Organoids. Organoids are 3-D cell structures with organ-like characteristics grown from adult stem cells. The Company is commercialising its platform, which is a powerful new enabling technology in early-stage drug discovery for multiple types of cancer.